ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-20

Price

$115.00

-0.04%

Score16.5Top Tier

Signals6/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 6

Volume0.8xvs 20d avg

Analysis

Arcellx (ACLX) is trading essentially flat at $115.00, perfectly pinned to the cash portion of its pending acquisition by Gilead Sciences ($115/share plus a $5 CVR). The exceptionally low realized volatility of 1.2% and the QUIET_STORM technical signal are textbook reflections of merger arbitrage consolidation following the February 2026 deal announcement. With Gilead securing all required regulatory approvals and extending the tender offer to April 27, the market is pricing in near-certain deal closure, a conviction bolstered by the RISK_ON macro regime and ultra-tight corporate credit spreads (0.80%) that eliminate financing risk.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUEBARGAIN HUNTER

Key Takeaways

Actionable Thesis: The stock is a pure merger arbitrage play pinned to the $115 cash deal price, leaving the $5 CVR as an optionality play for long-term holders.
Key Risk: Deal collapse due to a failure to secure a majority of tendered shares could send the stock plummeting back to its pre-acquisition baseline near $68.
What to Watch: The April 27, 2026 tender offer expiration date is the definitive milestone for the transaction's completion.

← Back to 2026-04-20 View Full ACLX History →Yahoo Finance &nearr;